Beneficial Actions of SGLT2 Inhibition and H2S Therapy in Heart Failure with Preserved Ejection Fraction

Authors

Jake Doiron, LSU Health Sciences Center - New OrleansFollow
Zhen Li, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
Huijing Xia, LSU Health Sciences Center - New OrleansFollow
Kyle B. Lapenna, LSU Health Sciences Center - New OrleansFollow
Timothy D. Allerton, Pennington Biomedical Research Center, Baton Rouge, LA
Daniel R. Kapusta, LSU Health Sciences Center - New OrleansFollow
David J. Lefer, LSU Health Sciences Center - New Orleans

Document Type

Conference Proceeding

Publication Date

4-24-2023

Publication Title

Journal of Clinical and Translational Science

Abstract

Association for Clinical and Translational Science, ACTS 2023, April 18 - 20, 2023, Washington DC

First Page

108

Volume

7

Issue

Supplement 1

Comments

Abstract 364

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.

Recommended Citation

Doiron, Jake; Li, Zhen; Xia, Huijing; Lapenna, Kyle B.; Allerton, Timothy D.; Kapusta, Daniel R.; and Lefer, David J., "Beneficial Actions of SGLT2 Inhibition and H2S Therapy in Heart Failure with Preserved Ejection Fraction" (2023). School of Graduate Studies Faculty Publications. 372.
https://digitalscholar.lsuhsc.edu/sogs_facpubs/372
10.1017/cts.2023.404